MEK inhibitors in non-V600 BRAF mutations and fusions

Mutations in BRAF at the 600th codon have proven sensitive to combination BRAF and MEK inhibition. Mutations outside this codon, however, are approximately as common but do not have approved targeted therapy approaches. Herein, we discuss targeting these non-V600 mutation and fusions in BRAF with ME...

Descripción completa

Detalles Bibliográficos
Autores principales: Johnson, Douglas B., Nebhan, Caroline A., Noel, Marcus S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2020
Materias:
Research Perspective
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7646828/
https://www.ncbi.nlm.nih.gov/pubmed/33216832
http://dx.doi.org/10.18632/oncotarget.27788
Descripción
Sumario:Mutations in BRAF at the 600th codon have proven sensitive to combination BRAF and MEK inhibition. Mutations outside this codon, however, are approximately as common but do not have approved targeted therapy approaches. Herein, we discuss targeting these non-V600 mutation and fusions in BRAF with MEK inhibitors.

Ejemplares similares